<DOC>
	<DOCNO>NCT02842333</DOCNO>
	<brief_summary>The investigator recently identify promiscuous HLA-DR-derived epitope human telomerase reverse transcriptase ( TERT ) call universal cancer peptide ( UCP ) , study tumor-specific CD4+ T cell response . The aim prospective preliminary study evaluate presence UCP-specific Th1 responses patient complete remission CML two year end Tyrosine Kinase Inhibitor ( TKi ) treatment .</brief_summary>
	<brief_title>Study Predictive Immunological Parameters Molecular Complete Remission Patients With Chronic Myelogenous Leukemia Chronic Phase Treated With Tyrosine Kinase Inhibitor</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>For cohort A : patient chronic myelogenous leukemia chronic phase deep molecular response ( MR4.0 ) persistent 2 year end TKi treatment patient total cessation TKi treatment sign write informed consent For cohort B : patient chronic myelogenous leukemia chronic phase , diagnosis relapse increase 1 year less stopping treatment TKIs ( inclusion patient TKi treatment relapse possible ) . sign write informed consent Exclusion Criteria ( patient ) : patient chronic treatment systemic corticoid immunosuppressive drug ( corticoid â‰¤ 10 mg/day allow ) active autoimmune disease , HIV , hepatitis C B virus patient medical psychiatric condition disease would make patient inappropriate entry study . patient guardianship , curator protection justice .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>